Invega Sustenna (paliperidone palmitate) is a prescription drug that’s used to treat schizophrenia and schizoaffective disorder. Invega Sustenna is given as an injection into your muscle by a ...

TITUSVILLE, N.J., May 24 /PRNewswire/ --New data on INVEGA® SUSTENNA® (paliperidone palmitate), a long-acting injectable medicine for schizophrenia, and new data on RISPERDAL® CONSTA® (risperidone ...

After incurring a loss in New Jersey federal court in 2021, Teva and Viatris have successfully resurrected challenges to the last remaining U.S. patent on a lucrative Johnson & Johnson schizophrenia ...

Janssen announced positive results of its PRIDE (Paliperidone Palmitate Research In Demonstrating Effectiveness) trial that compared schizophrenia medications. Results showed that once-monthly Invega ...

Janssen announced the submission of supplemental New Drug Applications (sNDAs) to the FDA for Invega Sustenna (paliperidone palmitate), an atypical long-acting antipsychotic for the treatment of ...

The program, which consists of two studies, will evaluate the safety, efficacy and tolerability of the new version of the drug. While the first study (n~500) will evaluate the safety, efficacy and ...

Schizophrenia is a mental health disorder that causes changes to the way a person thinks, acts, and behaves. People with schizophrenia may have hallucinations, delusions, disorganized behavior, and ...

UZEDY ® (1-month and 2-month subcutaneous risperidone for treatment of schizophrenia), is the first product based on Medincell's long-acting injection technology that reached commercial stage. UZEDY ...

(Reuters) -Teva Pharmaceutical and Viatris convinced a U.S. appeals court on Monday to revive their challenges to a patent covering a blockbuster Johnson & Johnson schizophrenia drug, giving them a ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. INVEGA SUSTENNA contains the active ingredient paliperidone palmitate.